FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067232011> ?p ?o ?g. }

• W2067232011 endingPage "354" @default.
• W2067232011 startingPage "349" @default.
• W2067232011 abstract "There is evidence that both carnitine and coenzyme Q 10 (Co Q), which are important for the functioning of myocardial mitochondria, are deficient in patients with congestive heart failure, in association with increased pro-inflammatory cytokines. It is possible that supplementation with ubiquinol and L-carnitine may protect these patients by decreasing inflammation.In a randomized, double-blind, placebo-controlled trial, the effects of carni Q-gel (2250 mg/d L-carnitine and 270 mg/d hydrosoluble ubiquinol) were examined for 12 weeks. Thirty-one patients with heart failure received intervention (group A) and another 31 patients served as controls (group B). Serum levels of interleukin (IL)-6, tumour necrosis factor (TNF)-alpha and IL-10 could be studied among 29 patients in each group. Statistical analysis was conducted by analysis of variance and chi square test.Echocardiographic ejection fractions were lower at baseline (38.8 + 7.6 vs. 39.3 + 6.7% in the intervention and control groups, respectively) among both group of patients, indicating class II-IV heart failure. Serum concentration of interleukin-6 (IL-6), a pro-inflammatory cytokine, was high (18.7 +/- 5.8 vs. 15.0 +/- 3.3 pg/ml, normal 0.0-3.9) and IL-10 (anti-inflammatory) was normal (3.4 +/- 1.5 vs. 2.9 +/- 1.0 pg/ml, the normal range is 1.5-3.1 pg/ml) in both groups at baseline. After 12 weeks, there was a marked reduction in IL-6 in the intervention group without such changes in the control group (7.6 +/- 1.5 vs. 11.4 +/- 2.5 pg/ml, P < 0.01. IL-10 showed only the non-significant decrease in both groups from the baseline levels (3.2 +/- 1.0 vs. 2.8 +/- 0.9 pg/ml). TNF-alpha, which was comparable at baseline (17.6 +/- 4.3 vs. 20.0 +/- 5.3 pg/ml), also showed a greater decline in the carni Q-gel group compared to the placebo group (12.5 +/- 3.3 vs. 17.2 +/- 3.2 pg/ml, P < 0.05). Baseline serum CoQ levels (0.21 +/- 0.11 vs. 0.19 +/- 0.10 microg/ml) were low; however, after 12 weeks, serum CoQ showed a significant increase in the carni Q-gel group as compared to the control group (2.7 +/- 1.2 and 0.76 +/- 0.14 microg/ml, respectively). After 12 weeks of treatment, the quality of life visual analogous scale revealed that dyspnoea, palpitation and fatigue, (NYHA class II-III-IV), which were present at rest in all patients at baseline, showed beneficial effects in the intervention group compared to the placebo group. The six-minute walk test showed that there was a significant greater benefit in walking, from the baseline distance in the intervention group (208 +/- 15.8 vs. 281 +/- 20.6 metres, P < 0.02) compared to the placebo group (218.4 +/- 17.6 vs. 260.7 +/- 19.3 metres, P < 0.05). The symptom scale indicated that the majority of patients showed improvement in the intervention group compared to the control group (28 vs. 16 patients, respectively, P < 0.05). Three patients in the intervention group had nausea and vomiting, which were controlled with symptomatic treatment.These findings indicate that treatment with ubiquinol + L-carnitine can cause a significant reduction in the pro-inflammatory cytokines that are neurohumoural precursors related to sympathetic and parasympathetic activity, which is impaired in patients with heart failure. There was no adverse effect on IL-10. There was a significant improvement in quality of life as well as decrease in NYHA-defined heart failure." @default.
• W2067232011 created "2016-06-24" @default.
• W2067232011 creator A5009370254 @default.
• W2067232011 creator A5033769407 @default.
• W2067232011 creator A5035643084 @default.
• W2067232011 creator A5039533232 @default.
• W2067232011 creator A5050076244 @default.
• W2067232011 creator A5064176841 @default.
• W2067232011 creator A5077980208 @default.
• W2067232011 creator A5080050045 @default.
• W2067232011 creator A5088396929 @default.
• W2067232011 date "2007-07-31" @default.
• W2067232011 modified "2023-10-06" @default.
• W2067232011 title "Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study." @default.
• W2067232011 cites W124016525 @default.
• W2067232011 cites W173467498 @default.
• W2067232011 cites W1872960871 @default.
• W2067232011 cites W1963492252 @default.
• W2067232011 cites W1973024029 @default.
• W2067232011 cites W1981282124 @default.
• W2067232011 cites W2005267038 @default.
• W2067232011 cites W2014029751 @default.
• W2067232011 cites W2034277702 @default.
• W2067232011 cites W2053242236 @default.
• W2067232011 cites W2065821636 @default.
• W2067232011 cites W2082419410 @default.
• W2067232011 cites W2098328918 @default.
• W2067232011 cites W2104179458 @default.
• W2067232011 cites W2131591245 @default.
• W2067232011 cites W2136094484 @default.
• W2067232011 cites W2146902372 @default.
• W2067232011 cites W2185786658 @default.
• W2067232011 cites W2417344508 @default.
• W2067232011 cites W2895974720 @default.
• W2067232011 cites W75296461 @default.
• W2067232011 doi "https://doi.org/10.2143/ac.62.4.2022278" @default.
• W2067232011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17824295" @default.
• W2067232011 hasPublicationYear "2007" @default.
• W2067232011 type Work @default.
• W2067232011 sameAs 2067232011 @default.
• W2067232011 citedByCount "38" @default.
• W2067232011 countsByYear W20672320112012 @default.
• W2067232011 countsByYear W20672320112013 @default.
• W2067232011 countsByYear W20672320112014 @default.
• W2067232011 countsByYear W20672320112015 @default.
• W2067232011 countsByYear W20672320112016 @default.
• W2067232011 countsByYear W20672320112018 @default.
• W2067232011 countsByYear W20672320112019 @default.
• W2067232011 countsByYear W20672320112020 @default.
• W2067232011 countsByYear W20672320112021 @default.
• W2067232011 countsByYear W20672320112022 @default.
• W2067232011 countsByYear W20672320112023 @default.
• W2067232011 crossrefType "journal-article" @default.
• W2067232011 hasAuthorship W2067232011A5009370254 @default.
• W2067232011 hasAuthorship W2067232011A5033769407 @default.
• W2067232011 hasAuthorship W2067232011A5035643084 @default.
• W2067232011 hasAuthorship W2067232011A5039533232 @default.
• W2067232011 hasAuthorship W2067232011A5050076244 @default.
• W2067232011 hasAuthorship W2067232011A5064176841 @default.
• W2067232011 hasAuthorship W2067232011A5077980208 @default.
• W2067232011 hasAuthorship W2067232011A5080050045 @default.
• W2067232011 hasAuthorship W2067232011A5088396929 @default.
• W2067232011 hasConcept C126322002 @default.
• W2067232011 hasConcept C134018914 @default.
• W2067232011 hasConcept C142724271 @default.
• W2067232011 hasConcept C14471203 @default.
• W2067232011 hasConcept C168563851 @default.
• W2067232011 hasConcept C185592680 @default.
• W2067232011 hasConcept C204787440 @default.
• W2067232011 hasConcept C27081682 @default.
• W2067232011 hasConcept C2776914184 @default.
• W2067232011 hasConcept C2778198053 @default.
• W2067232011 hasConcept C2778435403 @default.
• W2067232011 hasConcept C2778777121 @default.
• W2067232011 hasConcept C28859421 @default.
• W2067232011 hasConcept C29311851 @default.
• W2067232011 hasConcept C55493867 @default.
• W2067232011 hasConcept C71924100 @default.
• W2067232011 hasConcept C78085059 @default.
• W2067232011 hasConcept C90924648 @default.
• W2067232011 hasConceptScore W2067232011C126322002 @default.
• W2067232011 hasConceptScore W2067232011C134018914 @default.
• W2067232011 hasConceptScore W2067232011C142724271 @default.
• W2067232011 hasConceptScore W2067232011C14471203 @default.
• W2067232011 hasConceptScore W2067232011C168563851 @default.
• W2067232011 hasConceptScore W2067232011C185592680 @default.
• W2067232011 hasConceptScore W2067232011C204787440 @default.
• W2067232011 hasConceptScore W2067232011C27081682 @default.
• W2067232011 hasConceptScore W2067232011C2776914184 @default.
• W2067232011 hasConceptScore W2067232011C2778198053 @default.
• W2067232011 hasConceptScore W2067232011C2778435403 @default.
• W2067232011 hasConceptScore W2067232011C2778777121 @default.
• W2067232011 hasConceptScore W2067232011C28859421 @default.
• W2067232011 hasConceptScore W2067232011C29311851 @default.
• W2067232011 hasConceptScore W2067232011C55493867 @default.
• W2067232011 hasConceptScore W2067232011C71924100 @default.
• W2067232011 hasConceptScore W2067232011C78085059 @default.
• W2067232011 hasConceptScore W2067232011C90924648 @default.

• next